A new Big Ten Cancer Research Consortium study, led by Ruth O'Regan, MD, of the University of Wisconsin Carbone Cancer Center, is taking aim at androgen receptor positive triple negative breast cancer.
A Big Ten CRC study led by Lawrence Feldman, MD, of the University of Illinois Cancer Center, is testing pembrolizumab with Imprime PGG for metastatic non-small lung cancer patients whose tumors progressed during or after treatment with first-line platinum-based chemotherapy.
The Big Ten Cancer Research Consortium will host meetings for the Big Ten CRC Foundation, Cancer Center Directors, Steering Committee, and Clinical Trial Working Groups during ASCO 2017.
Perspectives: Steven K. Libutti, MD, FACS (pictured right), director, Rutgers Cancer Institute of New Jersey, Rutgers University; senior vice president of oncology services for RWJBarnabas Health.
